Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TPH1 | P17752 | 12/20 | 0.54 |
| ▸ | LDHA | P00338 | 1/20 | 0.48 |
| ▸ | PPARG | P37231 | 1/20 | 0.47 |
| ▸ | PPARA | Q07869 | 1/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.46 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.46 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.45 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2000467 | 1.00 | TPH1 (0.54) | TPH1LDHAPPARGPPARAPTPN1 | |
| SCHEMBL30040624 | 1.00 | TPH1 (0.54) | TPH1LDHAPPARGPPARAPTPN1 | |
| SCHEMBL1999882 | 0.89 | SRD5A2 (0.51) | TPH1PPARGPPARAPTPN1SLC7A5 | |
| SCHEMBL14601306 | 0.86 | LDHA (0.49) | LDHAPPARGPPARASMN1; SMN2 | |
| SCHEMBL2000541 | 0.86 | PPARG (0.55) | TPH1LDHAPPARGPPARAPTPN1 | |
| SCHEMBL7235666 | 0.84 | TPH1 (0.69) | TPH1LDHAPPARGPPARA | |
| SCHEMBL25311021 | 0.83 | SLC7A5 (0.60) | TPH1SLC7A5 | |
| SCHEMBL2005524 | 0.83 | SLC7A5 (0.60) | TPH1SLC7A5 | |
| SCHEMBL8771914 | 0.83 | KIF11 (0.46) | TPH1PPARGPPARASLC7A5SMN1; SMN2 | |
| SCHEMBL3901263 | 0.83 | SRD5A2 (0.46) | TPH1PPARGPPARAPTPN1SLC7A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250367263-A9 | Therapeutic Regimens and Methods for Treatment of Cardiovascular Risk Factors using a GLP-1R and GCGR Agonist | SPITFIRE PHARMA LLC (US) | 2025-12-04 | — | — | US | disclosed |
| US-20250288650-A1 | Therapeutic Regimens and Methods for Reducing Body Weight and/or Serum Lipids using a GLP-1R and GCGR Agonist | SPITFIRE PHARMA LLC (US) | 2025-09-18 | — | — | US | disclosed |
| US-20250281450-A1 | PEPTIDE PHARMACEUTICALS FOR TREATMENT OF NASH AND OTHER DISORDERS | MEDERIS DIABETES LLC (US) | 2025-09-11 | — | — | US | disclosed |
| EP-4611792-A1 | THERAPEUTIC REGIMENS AND METHODS FOR TREATMENT OF CARDIOVASCULAR RISK FACTORS USING A GLP-1R AND GCGR AGONIST | Spitfire Pharma LLC (US) | 2025-09-10 | — | — | EP | disclosed |
| US-20250262280-A1 | GLP-1R and GCGR Agonists, Formulations, and Methods of Use | SPITFIRE PHARMA LLC (US) | 2025-08-21 | — | — | US | disclosed |
| EP-4587045-A2 | THERAPEUTIC REGIMENS AND METHODS FOR REDUCING BODY WEIGHT IN A SUBJECT WITH FATTY LIVER DISEASE USING A GLP-1R AND GCGR AGONIST | Spitfire Pharma LLC (US) | 2025-07-23 | — | — | EP | disclosed |
| US-20250134963-A1 | Therapeutic Regimens and Methods for Lowering Blood Glucose and/or Body Weight using GLP-1R and GCGR Balanced Agonists | SPITFIRE PHARMA LLC (US) | 2025-05-01 | — | — | US | disclosed |
| US-12257229-B2 | Peptide pharmaceuticals for treatment of NASH and other disorders | SPITFIRE PHARMA LLC (US) | 2025-03-25 | — | — | US | disclosed |
| EP-4506017-A2 | IMPROVED PEPTIDE PHARMACEUTICALS FOR TREATMENT OF NASH AND OTHER DISORDERS | Mederis Diabetes, LLC (US) | 2025-02-12 | — | — | EP | disclosed |
| US-12171806-B2 | Therapeutic regimens and methods for lowering blood glucose and/or body weight using GLP-1R and GCGR balanced agonists | SPITFIRE PHARMA LLC (MD) | 2024-12-24 | — | — | US | disclosed |
| EP-3735295-A1 | IMPROVED PEPTIDE PHARMACEUTICALS FOR TREATMENT OF NASH AND OTHER DISORDERS | Mederis Diabetes, LLC (US) | 2020-11-11 | — | — | EP | disclosed |
| WO-2019136158-A1 | IMPROVED PEPTIDE PHARMACEUTICALS FOR TREATMENT OF NASH AND OTHER DISORDERS | SPITFIRE PHARMA, INC. (US) | 2019-07-11 | — | — | WO | disclosed |
| US-8883963-B2 | Peptidomimetics with glucagon antagonistic and GLP 1 agonistic activities | CADILA HEALTHCARE LIMITED (IN) | 2014-11-11 | — | — | US | disclosed |
| US-8383581-B2 | Short-chain peptides as parathyroid hormone (PTH) receptor agonist | CADILA HEALTHCARE LIMITED (IN) | 2013-02-26 | — | — | US | disclosed |
| US-8383581-B2 | Short-chain peptides as parathyroid hormone (PTH) receptor agonist | CADILA HEALTHCARE LIMITED (IN) | 2013-02-26 | — | — | US | disclosed |
| WO-2012120532-A2 | CYCLIC SHORT CHAIN PEPTIDES | CADILA HEALTHCARE LIMITED (IN) | 2012-09-13 | — | — | WO | disclosed |
| US-20120108496-A1 | SHORT-CHAIN PEPTIDES AS PARATHYROID HORMONE (PTH) RECEPTOR AGONIST | CADILA HEALTHCARE LIMITED (IN) | 2012-05-03 | — | — | US | disclosed |
| US-20120108496-A1 | SHORT-CHAIN PEPTIDES AS PARATHYROID HORMONE (PTH) RECEPTOR AGONIST | CADILA HEALTHCARE LIMITED (IN) | 2012-05-03 | — | — | US | disclosed |
| US-20120021972-A1 | PEPTIDOMIMETICS WITH GLUCAGON ANTAGONISTIC AND GLP 1 AGONISTIC ACTIVITIES | CADILA HEALTHCARE LIMITED (IN) | 2012-01-26 | — | — | US | disclosed |
| WO-2010128521-A2 | SHORT-CHAIN PEPTIDES AS PARATHYROID HORMONE (PTH) RECEPTOR AGONIST | CADILA HEALTHCARE LIMITED (IN) | 2010-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108496-A1 | SHORT-CHAIN PEPTIDES AS PARATHYROID HORMONE (PTH) RECEPTOR AGONIST | PTH1R, GIPR, PTMS | TPH1 1299/4885LDHA 2958/4885PPARG 243/4885 |
| US-20250288650-A1 | Therapeutic Regimens and Methods for Reducing Body Weight and/or Serum Lipids using a GLP-1R and GCGR Agonist | GLP1R, GCGR, GIPR | TPH1 773/4885LDHA 3316/4885PPARG 71/4885 |
| US-20250367263-A9 | Therapeutic Regimens and Methods for Treatment of Cardiovascular Risk Factors using a GLP-1R and GCGR Agonist | GLP1R, GCGR, GIPR | TPH1 1457/4885LDHA 4401/4885PPARG 29/4885 |
| US-12171806-B2 | Therapeutic regimens and methods for lowering blood glucose and/or body weight using GLP-1R and GCGR balanced agonists | GLP1R, GCGR, GIPR | TPH1 1021/4885LDHA 3405/4885PPARG 125/4885 |
| US-20250134963-A1 | Therapeutic Regimens and Methods for Lowering Blood Glucose and/or Body Weight using GLP-1R and GCGR Balanced Agonists | GLP1R, GCGR, GIPR | TPH1 1021/4885LDHA 3405/4885PPARG 125/4885 |
| US-12257229-B2 | Peptide pharmaceuticals for treatment of NASH and other disorders | GLP1R, IAPP, GPR119 | TPH1 4091/4885LDHA 2615/4885PPARG 83/4885 |
| US-20250281450-A1 | PEPTIDE PHARMACEUTICALS FOR TREATMENT OF NASH AND OTHER DISORDERS | GLP1R, IAPP, GPR119 | TPH1 4091/4885LDHA 2615/4885PPARG 83/4885 |
| US-20250262280-A1 | GLP-1R and GCGR Agonists, Formulations, and Methods of Use | GLP1R, GCGR, GPR119 | TPH1 2384/4885LDHA 4791/4885PPARG 109/4885 |
| US-20120021972-A1 | PEPTIDOMIMETICS WITH GLUCAGON ANTAGONISTIC AND GLP 1 AGONISTIC ACTIVITIES | GLP1R, GPR119, GIPR | TPH1 1635/4885LDHA 3279/4885PPARG 493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.